Riccardo Moia

Novara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy.

Journal: British journal of haematology

Published: May 15, 2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances

Published: April 16, 2026

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.

Journal: Cells

Published: March 20, 2026

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Journal: Hematological oncology

Published: February 14, 2026

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

Journal: HemaSphere

Published: February 04, 2026

Molecular Pathogenesis and Targeted Treatment of Richter Transformation.

Molecular Pathogenesis and Targeted Treatment of Richter Transformation.

Journal: Biomedicines

Published: December 31, 2025

Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.

Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy.

Journal: Hematological oncology

Published: December 17, 2025

Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL).

Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL).

Journal: Cancers

Published: November 20, 2025

Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study.

Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study.

Journal: Hematological oncology

Published: November 15, 2025

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances

Published: October 22, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Showing 1-12 of 97

Last Updated: 09/26/2026